Serum digoxin levels (SDL) were compared with tolerance for the rapidly acting cardiac aglycone, acetyl strophanthidin (AS). AS titration tests were performed on 133 patients with diverse cardiac disorders. All were receiving maintenance digoxin. Both exquisite AS sensitivity and tolerance for a 1.0 mg AS were associated with a wide range of SDL values. Concordance and discordance between the two methods in assessing degree of digitalization were evaluated by considering SDL of 1.4 ng/ml to be the mean value for patients without glycoside-induced cardiac arrhythmia. An SDL of <1.5 ng/ml with tolerance for 1.0 mg AS and an SDL of >1.4 ng/ml with sensitivity to 1.0 mg AS or less constituted concordant responses. An SDL of <1.5 ng/ml with intolerance for 1.0 mg or less AS and an SDL of >1.4 ng/ml with tolerance for 1.0 mg AS comprised discordant responses. In 60 of 144 (42%) AS titrations discordant results were observed. Severe pulmonic, coronary, and aortic valvular heart disease, as well as old age, contributed to unusual AS sensitivitv. Titration with AS clarified pharmacologic quantification of SDL by providing insight into optimum therapeutic glycoside dose. Development of a radioimmunoassay for digoxin promised to resolve questions concerning appropriate dosage of this commonly employed digitalis glycoside. Several studies indicated that the quantity of drug present in the serum could be determined with precision. 9 Serum digoxin concentration measurements delineated a therapeutic range of values and provided a convenient marker for differentiating toxic from nontoxic patients with cardiac arrhythmias.20' 21 Eighty-five percent of patients with manifestations suggesting digitalis intoxication showed blood levels above 2.0 ng/ml; while a similar percentage of those without evidence of overdosage had concentrations below this value.22 However, the range of overlap between toxic and nontoxic groups was wide, from 1.6-3.0 ng/ml.22 More recent reports indicate an even wider range of overlap, extending through virtually the entire serum digoxin concentration span encountered clinically.23
Development of a radioimmunoassay for digoxin promised to resolve questions concerning appropriate dosage of this commonly employed digitalis glycoside. Several studies indicated that the quantity of drug present in the serum could be determined with precision. 9 Serum digoxin concentration measurements delineated a therapeutic range of values and provided a convenient marker for differentiating toxic from nontoxic patients with cardiac arrhythmias.20' 21 Eighty-five percent of patients with manifestations suggesting digitalis intoxication showed blood levels above 2.0 ng/ml; while a similar percentage of those without evidence of overdosage had concentrations below this value. 22 However, the range of overlap between toxic and nontoxic groups was wide, from 1.6-3.0 ng/ml.22 More recent reports indicate an even wider range of overlap, extending through virtually the entire serum digoxin concentration span encountered clinically. 23 Implicit in the clinical use of serum digoxin levels for assessing the state of digitalization are two assumptions: first, that blood levels reflect faithfully myocardial drug concentrations, and second, that a given concentration is associated with specific effect.
These assumptions, however, may not always be valid. Though serum digoxin concentration probably does provide a measure of myocardial binding in the steady state, a variety of metabolic and intrinsic myocardial Circulation These categories were utilized to characterize degrees of digitalis sensitivity ranging from none to extreme (table 1) .
Comparison between Serum Digoxin Levels and Acetyl Strophanthidin Tolerance Serum digoxin levels were compared with myocardial response to AS. To make such a comparison, a blood digoxin level was selected below which digitalis intoxication would be considered unlikely. Several reports have indicated that the mean SDL values for patients without glycosideinduced cardiac arrhythmia is 1.3-1.4 ng/ml.'3-5 20 , 21 Therefore, if a patient's SDL were <1.5 ng/ml, it was assumed he would show no sensitivity to AS. If his SDL exceeded 1.4 ng/ml, he should exhibit sensitivity to AS. These categories constituted a concordant response between the two methods. AS tolerance of 1.0 mg with SDL of >1.4 ng/ml and AS tolerance of <1.0 mg with SDL of 1.4 ng/ml or less comprised a discordant response between the two methods.
Results
In 59 of the 144 AS tests, full tolerance to this drug was manifest (group I response). The mean SDL was 1.0 ± 0.08 ng/ml (SEM). By contrast, the 53 tests in patients who developed arrhythmias with 1.0 mg of AS or less, (group III or IV response) had a SDL of 1.77 + 0.20 ng/ml (SEM) (P < 0.01) ( fig. 1) responding with arrhythmia to AS (groups III and IV) had a BUN > 30 mg% than those (5 of 32, 15%) with gastrointestinal side effects (group II) or those (6 of 59, 10%) fully tolerant of AS (group I). More striking, however, was the effect of age upon AS tolerance. Cases fully tolerant of 1.0 mg AS (group I) were significantly younger (58.3 ± 1.3 years SEM) than subjects developing gastrointestinal side effects (group II) (63.5 ± 1.8 years) (P < 0.05) or arrhythmic side effects with 0.7-1.0 mg AS (group III) (63.3 ± 1.9 years) (P < 0.05). Group IV cases developing If one were to select an average serum digoxin conentratiorn which xvotld separate a majority of digitalis toxic from a majority of nontoxic patients, such a concentration might be 1.4 ng/ml. '3'5' 20, 21 On the basis of stuch an arbitrary demarcation, the response to AS testing was classified into two categories, one in which there vas agreement between the two methods -the concorcdant group and the other in which a disparity in result xvas observed -the discordant group. There vere tvo subgroups in each. In the concordant group, subgroup (a) consisted of patients with SDL of less thaln 1.4 In 84 of 144 AS tests, or in 58%, the result was concordant, w hile in 60 tests discordance was observed (42c%) (table 3). In 40 AS tolerance tests, though the SDL was less than 1.5 ng/ml, a toxic reaction followed A 67-year-old femnale with severe mitral regturgitatiorn. .1,1"',"'Lil', 1 7PW1171MM1-11,7-TI-1. -, ,711-ME,flaif i l '
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Discussion
The introduction of radioimmunoassay technique for quantifying blood glycoside concentration represents a significant advance. It will necessarily contribute to rationalizing digitalis treatment which is now still based on the original principles defined by Withering nearly two centuries ago.37 But, as with any new development, there are tendencies to lose sight of the limitations implicit in a technique. A serum glycoside level in a stable patient without renal impairment on constant maintenance digitalis therapy probably reflects myocardial drug concentration.38 Yet, the extracellular drug represents but a small fraction of glycosides distributed in the tissues, and fourfold variations in serum to myocardial digoxin ratios have been demonstrated between individual patients.38' 39 Changes in electrolyte and hormonal balance are known to alter cardiac to serum digoxin ratios,40 41 while ischemia can affect the distribution of digoxin within the myocardium.42 Moreover, fluctuations in serum digoxin concentration are influenced by absorbtion, distribution, metabolism and excretion of the drugs whereas myocardial susceptibility to the toxic action of digitalis can be rapidly altered by other factors.43'Ẁ hat, then, is the significance of a blood glycoside level in the individual patient? It has been stated that 85% to 90% of toxic patients had levels of 2 ng/ml or greater and that 85% to 87% of nontoxic patients had levels of less than 2 ng/ml.'3' 22 Others have likewise reported significantly higher serum digoxin levels in patients with presumed digitalis intoxication, compared with nontoxic subjects free of adverse drug effects.3 20, 21, 4548 There are two possible objections to the above conclusions; first, that extremes -those who are definitely regarded overdigitalized against those who are unequivocally free of digitalis intoxication -are being compared. But even in these studies, there are substantial overlaps at both the higher and lower digoxin blood level range. A more serious criticism is that a judgment concerning the presence of digitalis intoxication is rarely certain. Both subjective complaints as well as objective manifestations lack specificity for digitalis intoxication. Even ventricular bigeminal rhythm in the digitalized subject may be an expression of inadequate digitalization. In fact, conclusions correlating arrhythmias due to digitalis intoxication with levels of serum glycoside may be circularly derived. Where 17 Clinical application of AS tolerance testing rests upon the additional observation that action of this drug is additive to that of cardiac glycosides already in the body.17 Digoxin and AS have combined effects on cardiac automaticity and, over a wide range of SDL (0-14 ng/ml), SDL is inversely correlated with AS tolerance. 27 The selection of an AS dose of 1.0 mg was based on observations derived from 430 AS tests performed during the past five years. It has been noted that patients with atrial fibrillation, who, while on maintenance digitalis, have well-controlled ventricular rates, tolerate this dose without adverse effects. On the other hand, those who develop ventricular arrhythmia with 0.6 mg or less, generally are close to digitalis intoxication, or, indeed, are already experiencing the effects of glycoside overdosage. The choice of 1.4 ng/ml as the cutoff for differentiating between concordant and discordant responses to AS was based on the observation that this represents a mean value for large groups of digitalized patients free of any evidence of intoxication. 13-15. 20 Both AS testing and SDL measurements showed the effects of hyperthyroidism upon the heart. These methods gave concordant results in two cases with recurrent arrhythmias. SDL of 0.6-1.0 ng/ml with a digoxin maintenance dose of 0.5 mg/day was consistent with the observation that hyperthyroid patients exhibit lower SDL levels than euthyroid subjects.4'
The high tolerance for AS despite moderately large maintenance digoxin dose confirmed previous work showing that unusually large doses of this drug were necessary to control ventricular response rates in atrial fibrillation.6' By contrast, one patient, in whom hypothyroidism complicated coronary heart disease, exhibited a SDL of 1.0 ng/ml while receiving 0.125 mg digoxin daily.4`Exquisite sensitivity to AS was nonetheless demonstrable, as ventricular premature beat frequency increased after only 0.4 mg of AS. Perhaps the most striking examples of discordance between SDL and AS tolerance occurred in six patients with chronic obstructive lung disease. These individuals had cor pulmonale and coronary heart disease, as well. Pulmonary infections triggered respiratory failure with concomitant hypoxemia, which in turn precipitated left ventricular dysfunction and congestive heart failure. Recurrent atrial tachyarrhythmias, refractory to cardioversion, were associated with digoxin blood levels of 1.0 ng/ml or less. Guided by repetitive AS testing, protracted sensitivity could be shown after stopping digitalis. Generally, it persisted for a week or longer, at which time the SDL was 0.4 ng/ml or less. By the time tolerance to AS developed, the arrhythmias had disappeared.
It can be argued that factors other than myocardial sensitivity influenced cardiac tolerance for AS. Drug distribution space and metabolism are known to be important determinants of serum glycoside levels and myocardial glycoside concentration after fixed digoxin dose. AS tolerance in dogs has not been shown to correlate with body weight (B. Lown, unpublished observations). In both dogs and normal human subjects, AS appears to be eliminated through hepatic and gastrointestinal rather than renal routes. 50 The degree of plasma protein binding of AS, its distribution space, and the effects of congestive heart failure and liver dysfunction upon AS catabolism remain unknown. Many examples of discordant results between SDL and AS titration testing, however, could not be wholly accounted for by deranged liver function or a shrunken skeletal muscle mass, diverting larger amounts of AS to the heart and thereby reducing myocardial tolerance.
Pharmacologic quantification provides significant insight in therapeutic management. In the case of digoxin, serum concentration measurements yield valuable information about the composite of drug absorption, distribution and excretion. The crucial question does not relate to SDL alone, but rather to whether an optimal therapeutic effect is being achieved and toxic action eschewed. If the blood level is high, adverse reactions are absent, and therapeutic effect not yet accomplished, there is need for more drug; on the other hand, in the presence of a low blood level, the presence of a clearly toxic response mandates less or no further drug administration.
(ircildationz, Volume XLIX, June 1974 In selecting the optimal dose of digitalis, physicians will continue to utilize biologic titration. Acetyl strophanthidin tolerance testing, by recapitulating the titration process within a brief time interval, will rapidly establish myocardial sensitivity, and will give SDL measurements added meaning.
